PRINT OUT

News Release 2013

November 11, 2013 Presentation Material for IR Meeting <PDF>
November 07, 2013 Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2013 <PDF>
September 30, 2013 Nippon Shinyaku and Pfizer conclude exclusive sales promotion consignment contract regarding "Tramal® Capsule" and "NS-24" for the treatment of cancer pain and chronic pain <HTML>
September 26, 2013 Launch of "LUNABELL® tablets ULD" for dysmenorrhea <HTML>
August 29, 2013 Cialis® Becomes #1 Share in the Worldwide Erectile Dysfunction (ED) Drug Market <HTML>
August 07, 2013 Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2013 <PDF>
August 07, 2013 Presentation Material for IR Meeting <PDF>
June 14, 2013 Nippon Shinyaku receives marketing authorization of "Tramal® Capsule 25mg" and "Tramal® Capsule 50mg" in Japan for the treatment of chronic pain as an indication extension <HTML>
May 27, 2013 Launch of Regtect® Tablets 333mg, the first approved drug in Japan for support maintenance of abstinence in patients with alcohol dependence <HTML>
May 15, 2013 Presentation Material for IR Meeting <PDF>
May 13, 2013 Outline of Consolidated Financial Results for the Year Ended March 31, 2013 <PDF>
May 09, 2013 Clinical Study Starts for the Treatment of Duchenne Muscular Dystrophy: the First Clinical Study of an Antisense Oligonucleotide Discovered in Japan <HTML>
March 25, 2013 Nippon Shinyaku Co., Ltd, obtains approval for Regtect® Tablet 333mg for support maintenance of abstinence in patients with alcohol dependence <HTML>
March 07, 2013 Dainippon Sumitomo Pharma and Nippon Shinyaku sign a license agreement for SMP-986, a therapeutic agent for urology <HTML>
February 06, 2013 Presentation Material(FY2012 3Q) <PDF>
February 06, 2013 Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2012 <PDF>
get_adobe_reader
page-top